

Express Mail No.: EV452776538US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Swiercz et al. Confirmation No.: 8301

Serial No.: 10/506,406 Art Unit: 1653

371 Filing Date: March 14, 2005 Examiner: Robinson, Hope A.

For: MODIFIED Attorney Docket No: 9471-011-999

PLASMINOGEN CAM No.: 209025-999010

ACTIVATOR INHIBITOR
TYPE-1 AND METHODS

BASED THEREON

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office ("Office") of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references C45-C48 which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant." Copies of references C45-C48 are submitted herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), it is believed that no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date:

June 27, 2006

By: Susie S. Cheng

JONES DAY

222 East 41st Street

New York, N.Y. 10017-6702

212-326-3939

Enclosures

Express Mail No.: EV452776538US

JUN 2 7 2006 EFE

EFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

	Sheet 1 of 1
ATTY. DOCKET NO. 9471-011-999	APPLICATION NO. 10/506,406
APPLICANT Swiercz et al.	
FILING DATE March 14, 2005	art unit 1656

			U.S. PAT	ENT DOCUMENTS		
*Examiner Initial		Document Number	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
			FOREIGN P	PATENT DOCUMENTS		
		Foreign Patent Document Country Code, Number, Kind Code (If Known)	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Т
		NON	PATENT L	ITERATURE DOCUMENTS		
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)				Т
	C45	CHOROSTOWSKA-WYNIMKO et al., 2002, "Cysteine mutations of plasminogen activator inhibitory type 1 extend its half-life. Implication for inhibition of cancer angiogenesis." Proc. Amer. Associat. For Can. Res. Ann. Meeting, 43:141				
	C46	17 C 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
	C47	SIMONOVIC et al., 2000, "The native metastable fold of Cl-inhibitor is stabilized by disulfide bonds." Biochimica et Biophysica Acta. 1481(1): 97-102				
	C48	TUCKER et al., 1995, "Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition," Nat. Struct. Biol. 2(6): 442-445				

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.